Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Solution LLC

Neither a doctor nor a teaching hospital

Research payments

$142,496

42 payments

Through program year 2025, Clinical Research Solution LLC is reported as receiving $142,496 in research payments, across 42 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $39,347 10
2024 Research $46,044 7
2023 Research $25,694 12
2022 Research $14,411 8
2020 Research $17,000 5

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $27,257 1 payment
  2. Argenx US, Inc. $20,472 5 payments
  3. E.R. Squibb & Sons, L.L.C. $16,722 2 payments
  4. Pfizer Inc. $12,500 6 payments
  5. Bausch Health US, LLC $11,000 2 payments
  6. Amgen Inc. $10,000 1 payment
  7. Gilead Sciences, Inc. $9,000 1 payment
  8. SK Life Science, Inc. $8,725 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $8,000 4 payments
  10. Teva Pharmaceuticals USA, Inc. $7,817 15 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function $27,257 1 payment
  2. A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC $20,472 5 payments
  3. A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $11,787 1 payment
  4. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $11,000 2 payments
  5. P2 UC $10,000 1 payment
  6. Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $9,000 1 payment
  7. Ykp3089c049 $8,725 3 payments
  8. A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice $7,817 15 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled 12Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $7,500 2 payments
  10. Efficacy and Safety of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Crohn?S Disease (Carmen CD 307) $7,000 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record